Rpigat 2.5 (Rivaroxaban) 2.5mg

RPIGAT 2.5 is a prescription anticoagulant medication containing 2.5 mg of the active ingredient Rivaroxaban. Formulated as an oral tablet, it belongs to the class of medications known as direct Factor Xa inhibitors. It is primarily prescribed to help reduce the risk of serious blood clot formation in patients with specific cardiovascular conditions.

Strength

2.5mg

Pack Size

60s

Storage

Below 25°C

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

RPIGAT 2.5 is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are determined to be at a high risk of ischemic events. It is typically used in combination with antiplatelet therapy, such as low-dose aspirin, as directed by a healthcare professional.

Side Effects

Common side effects associated with RPIGAT 2.5 include minor bleeding, bruising, nausea, dizziness, headache, and localized swelling. Because this medication reduces blood clotting, it carries a risk of serious or major bleeding events, which require immediate medical intervention.

Precautions & Warnings

RPIGAT 2.5 is a Schedule H prescription drug in India and must only be taken under strict medical supervision. It should be used with caution in patients with active pathological bleeding, severe renal impairment, moderate-to-severe hepatic impairment, or those undergoing surgery. Pregnant or breastfeeding individuals should consult their doctor, as the safety profile during pregnancy is not fully established.

Avoid Interactions

Rivaroxaban can interact with other anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), which may significantly increase the risk of bleeding. Additionally, strong inhibitors or inducers of CYP3A4 and P-glycoprotein (P-gp), such as certain azole antifungals, HIV protease inhibitors, or rifampicin, can alter the concentration of RPIGAT 2.5 in the body.

Frequently Asked Questions

RPIGAT 2.5 is a prescription anticoagulant tablet containing 2.5mg of Rivaroxaban. It is used to prevent atherothrombotic events, such as heart attacks or strokes, in adult patients diagnosed with coronary artery disease (CAD) or peripheral artery disease (PAD), usually in combination with aspirin.

RPIGAT 2.5 works as a direct Factor Xa inhibitor. By selectively blocking Factor Xa—a key enzyme in the blood clotting process—it interrupts the coagulation cascade, thereby reducing the formation of blood clots in the blood vessels.

Yes, RPIGAT 2.5 is commonly referred to as a blood thinner, though medically it is classified as an anticoagulant. It does not actually thin the blood but rather increases the time it takes for blood clots to form.

Because RPIGAT 2.5 reduces blood clotting, it increases the risk of bleeding. Minor bruising or nosebleeds can occur, but if you experience severe, prolonged, or unexplained bleeding, blood in your urine or stool, or coughing up blood, seek emergency medical attention immediately.

No, RPIGAT 2.5 is classified as a Schedule H prescription drug in India. It cannot be purchased over the counter and must only be dispensed by a licensed pharmacist with a valid prescription from a registered medical practitioner.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.